Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Oakmark Global Fund David G. Herro, Tony Coniaris, Eric Liu, M. Colin Hudson, John A. Sitarz | “AstraZeneca is one of the largest pharmaceutical companies in the world. It researches, develops and commercializes prescription medicines designed to treat lung and breast cancers, cardiorenal diseases, respiratory problems and other rare diseases. We believe AstraZeneca's robust on-market portfolio and sector-leading late-stage pipeline provide an attractive growth profile. Moreover, we believe the company can build on its long track record of a productive research and development program, thanks to its innovative culture and exceptional management team. In our view, CEO Pascal Soriot is one of the industry's best executives, and he has cultivated a deep bench of talent, a robust decision-making framework and a differentiated R&D culture that should drive strong growth for years to come, in our view. Recent concerns over United States regulations have overshadowed AstraZeneca's merits and weighed on the broader pharmaceutical industry. This opened a window for us to purchase shares of this company at a price well below our estimate of its intrinsic value.” | NEUTRAL | Q2 2026 Jul 15, 2026 | View Pitch |
American Century International Growth Fund Rajesh Gandhi, Jim Zhao | “AstraZeneca is one of the largest pharmaceutical companies in the world. It researches, develops and commercializes prescription medicines designed to treat lung and breast cancers, cardiorenal diseases, respiratory problems and other rare diseases. We believe AstraZeneca's robust on-market portfolio and sector-leading late-stage pipeline provide an attractive growth profile. Moreover, we believe the company can build on its long track record of a productive research and development program, thanks to its innovative culture and exceptional management team. Recent concerns over United States regulations have overshadowed AstraZeneca's merits and weighed on the broader pharmaceutical industry, opening a window to purchase shares well below intrinsic value. BSD Analysis: AstraZeneca has rebuilt its pipeline into one of the strongest in global pharma. Oncology and rare disease franchises drive durable growth beyond pandemic optics. Geographic diversification reduces single-market risk. Investors worry about patent cliffs and miss pipeline depth. Manufacturing scale supports rapid launch execution. Capital allocation balances R&D and returns effectively. This is big pharma executing with momentum rather than defending legacy.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
American Century International Growth Fund Rajesh Gandhi, Jim Zhao | “AstraZeneca. The company's share price rose after it presented successful phase 3 trial results for a hypertension treatment. Investors were also encouraged after several pharmaceutical companies, including AstraZeneca, agreed to subsidized pricing on key drugs, which avoided worst-case scenarios. BSD Analysis: AstraZeneca has quietly become one of the strongest execution stories in global pharma. Its oncology and rare disease franchises are deep, diversified, and still growing. Unlike one-drug wonders, AstraZeneca's pipeline actually replaces revenue before cliffs arrive. Emerging markets exposure adds growth but also volatility. Pricing pressure exists, but innovation quality keeps payers engaged. Capital allocation balances R&D ambition with financial discipline. Margins expand as newer therapies scale. This is not defensive pharma anymore. It's innovation-led compounding with global reach.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
American Century International Growth Fund Rajesh Gandhi, Jim Zhao | “U.K. biopharmaceutical maker AstraZeneca was a bright spot in the pharmaceutical side of health care. While health care stocks have been weak overall, we view AstraZeneca as benefiting from moderating U.S. pricing pressures and improving visibility following policy uncertainty. The company continues to execute well across its late-stage pipeline and remains positioned to deliver sustainable revenue growth despite sector-wide headwinds. BSD Analysis: AstraZeneca has quietly built one of the deepest large-cap pharma pipelines, anchored by oncology and rare disease franchises that actually move the needle. Growth is driven by volume and innovation rather than price inflation optics, which matters politically. The post-COVID hangover distorted sentiment, but core drugs continue to gain share globally. Emerging markets add durability that peers often lack. Investors worry about patent cliffs, yet the pipeline breadth meaningfully reduces single-asset risk. R&D productivity has been consistently strong, not episodic. Margin expansion comes from scale and mix, not financial engineering. AstraZeneca doesn't need heroic M&A to grow. This is pharma execution compounding while the market looks elsewhere.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
